文献速递骨质疏松与钙磷/甲状旁腺

多次连续骨密度监测在接受抗骨吸收治疗的骨质疏松女性中价值有限

Diminishing Value from Multiple Serial Bone Densitometry in Women Receiving Antiresorptive Medication for Osteoporosis.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本研究基于加拿大马尼托巴省行政数据库的队列,纳入1369例接受抗骨吸收药物且完成3次连续骨密度(BMD)测量的绝经后女性。结果显示,仅1.4%的女性在两个监测间期均出现BMD下降,仅3.2%(脊柱)和7.4%(髋部)从基线至最终BMD下降,提示多次连续BMD监测以识别持续应答不佳者的价值有限。

要点

  • 在接受抗骨吸收治疗的绝经后女性中,仅1.4%出现两个监测间期BMD均下降。
  • 从基线至最终BMD,脊柱和髋部BMD下降者分别仅3.2%和7.4%。
  • 多次连续BMD监测以识别持续应答不佳者的临床价值应被质疑。

核心结论

  • 在高依从性接受抗骨吸收治疗的骨质疏松女性中,极少数出现重复BMD测量下的持续骨密度丢失。
  • 多次连续BMD监测以检测持续应答不佳者的价值应被质疑。

研究设计与样本

  • 队列研究,使用加拿大马尼托巴省单一支付政府卫生系统的行政数据库。
  • 纳入1369例40岁及以上、接受抗骨吸收药物且完成3次连续BMD测量的绝经后女性,排除停药或换药者。

主要发现

  • 第一个监测间期,脊柱和髋部BMD下降的女性分别占3.2%和6.5%。
  • 第二个监测间期,脊柱和髋部BMD下降的女性分别占8.0%和16.9%。
  • 仅1.4%的女性在两个监测间期均出现BMD下降。
  • 整个治疗间期,脊柱和髋部BMD下降的女性分别仅3.2%和7.4%。
  • 平均BMD监测间期分别为3.0(0.8)年和3.2(0.8)年。

关键数值与推荐

  • 应答不佳定义一:两个监测间期均出现BMD下降。
  • 应答不佳定义二:从基线至最终BMD下降。

临床怎么用

  • 对于高依从性接受抗骨吸收治疗的骨质疏松女性,多次连续BMD监测以识别持续应答不佳者的价值有限。
  • 临床决策时应考虑避免不必要的重复BMD监测。

局限性

  • 结果可能不适用于抗骨吸收药物依从性差或使用合成代谢治疗的情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The value of serial bone mineral density (BMD) monitoring while on osteoporosis therapy is controversial. OBJECTIVE: We determined the percentage of women classified as suboptimal responders to therapy with antiresorptive medications according to 2 definitions of serial BMD change. METHODS: This was a cohort study using administrative databases at a single-payer government health system in Manitoba, Canada. Participants were postmenopausal women aged 40 years or older receiving antiresorptive medications and having 3 sequential BMD measures. Women stopping or switching therapies were excluded. The percentage of women whose spine or hip BMD decreased significantly during the first or second interval of monitoring by BMD was determined. Suboptimal responder status was defined as BMD decrease during both monitoring intervals or BMD decreased from baseline to final BMD. RESULTS: There were 1369 women in the analytic cohort. Mean BMD monitoring intervals were 3.0 (0.8) and 3.2 (0.8) years. In the first interval, 3.2% and 6.5% of women had a decrease in spine or hip BMD; 8.0% and 16.9% had decreases in the second monitoring interval; but only 1.4% showed repeated losses in both intervals. Considering the entire treatment interval, only 3.2% and 7.4% showed BMD loss at spine or hip. Results may not apply to situations of poor adherence to antiresorptive medication or anabolic therapy use. CONCLUSION: Among women highly adherent to antiresorptive therapy for osteoporosis, a very small percentage sustained BMD losses on repeated measures. The value of multiple serial BMD monitoring to detect persistent suboptimal responders should be questioned.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kline GA, Morin SN, Feldman S, et al. Diminishing Value from Multiple Serial Bone Densitometry in Women Receiving Antiresorptive Medication for Osteoporosis. J Clin Endocrinol Metab. 2021. PMID: 33784384. doi:10.1210/clinem/dgab211

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。